期刊
CANCER LETTERS
卷 528, 期 -, 页码 31-44出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.12.021
关键词
Ovarian cancer; AZD5153; PDX; PDO; palbociclib
类别
This study found that CDK4/6 inhibitor palbociclib faced resistance in multiple ovarian cancer models, but adding BRD4 inhibitor AZD5153 could overcome this issue, and the combination of the two demonstrated synergistic effects in inducing cell cycle arrest and increasing apoptosis.
The CDK4/6 inhibitor, palbociclib has recently entered clinic-trial stage for breast cancer treatment. However, translating its efficacy to other solid tumors has been challenging, especially for aggressive solid tumors. We found that the effect of palbociclib as a single agent was limited due to primary and acquired resistance in multiple ovarian cancer (OC) models. Among these, patient-derived organoid and xenograft models are two most representative models of drug responsiveness in patients with OC. In preclinical models, this study demonstrated that activated MAPK/PI3K-AKT pathway and cell cycle-related proteins induced the resistance to palbociclib, which was overcome by the addition of the bromodomain protein 4 (BRD4) inhibitor AZD5153. Moreover, this study revealed that AZD5153 and palbociclib had a synergistic lethal effect on inducing the cell cycle arrest and increasing apoptosis, even in RB-deficient cell lines. Based on these results, it is anticipated that this class of drugs, including AZD5153, which inhibit the cell cycle-related protein and MAPK/PI3K-AKT pathway, will exhibit synergistic effects with palbociclib in OC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据